[go: up one dir, main page]

ATE119198T1 - Verfahren zur herstellung von proteinen mittels rekombinanter dna. - Google Patents

Verfahren zur herstellung von proteinen mittels rekombinanter dna.

Info

Publication number
ATE119198T1
ATE119198T1 AT89303767T AT89303767T ATE119198T1 AT E119198 T1 ATE119198 T1 AT E119198T1 AT 89303767 T AT89303767 T AT 89303767T AT 89303767 T AT89303767 T AT 89303767T AT E119198 T1 ATE119198 T1 AT E119198T1
Authority
AT
Austria
Prior art keywords
recombinant dna
producing proteins
host cell
synthesised
dna sequence
Prior art date
Application number
AT89303767T
Other languages
English (en)
Inventor
Raymond John Owens
Gregory Paul Winter
Lutz Riechmann
Geoffrey Thomas Yarranton
Mark William Bodmer
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE119198(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888809050A external-priority patent/GB8809050D0/en
Priority claimed from GB888811342A external-priority patent/GB8811342D0/en
Priority claimed from GB888820284A external-priority patent/GB8820284D0/en
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of ATE119198T1 publication Critical patent/ATE119198T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89303767T 1988-04-16 1989-04-17 Verfahren zur herstellung von proteinen mittels rekombinanter dna. ATE119198T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888809050A GB8809050D0 (en) 1988-04-16 1988-04-16 Expression of antibody heavy & light chain variable domains as an fv-fragment
GB888811342A GB8811342D0 (en) 1988-05-13 1988-05-13 Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
GB888820284A GB8820284D0 (en) 1988-08-26 1988-08-26 Method for producing recombinant dna proteins

Publications (1)

Publication Number Publication Date
ATE119198T1 true ATE119198T1 (de) 1995-03-15

Family

ID=27263864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89303767T ATE119198T1 (de) 1988-04-16 1989-04-17 Verfahren zur herstellung von proteinen mittels rekombinanter dna.

Country Status (9)

Country Link
EP (1) EP0338745B1 (de)
JP (2) JP3105898B2 (de)
AT (1) ATE119198T1 (de)
AU (1) AU627183B2 (de)
CA (1) CA1341411C (de)
DE (1) DE68921364T2 (de)
ES (1) ES2070172T3 (de)
GR (1) GR3015248T3 (de)
WO (1) WO1989009825A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
AU706056B2 (en) * 1995-10-13 1999-06-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxin containing a disulfide-stabilized antibody fragment
AU7288196A (en) * 1995-10-20 1997-05-15 Ciba-Geigy Ag Process for the preparation of a single chain fv antibody fragment
EP1378525A3 (de) 1996-06-07 2004-01-14 Neorx Corporation Humanisierte Antikörper die and das gleiche Antigen wie Antikörper NR-LU-13 binden und deren Verwendung in "Pretargeting" Verfahren
JP2000164361A (ja) 1998-11-25 2000-06-16 Tdk Corp 有機ｅｌ素子
HK1047236A1 (zh) 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
JP4819285B2 (ja) 2000-05-16 2011-11-24 トーマス・ジェファーソン・ユニバーシティー 狂犬病ウイルス特異的ヒトモノクローナル中和抗体及び核酸及び関連する方法
SI2508596T1 (sl) 2002-02-21 2016-01-29 Institute Of Virology Slovak Academy Of Sciences Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe
MXPA05000832A (es) 2002-07-19 2005-10-19 Beth Israel Hospital Metodos de diagnosticar y tratar pre-eclampsia o eclampsia.
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
EP2332990A1 (de) 2004-03-19 2011-06-15 Imclone LLC Humaner Anti-Epidermiswachstumsfaktor-Rezeptor-Antikörper
SG155257A1 (en) 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
CA2590671A1 (en) 2004-11-18 2006-05-26 Imclone Systems Incorporated Antibodies against vascular endothelial growth factor receptor-1
US7598043B2 (en) 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
PL2100618T3 (pl) 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
JP5164167B2 (ja) 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
CA2658276A1 (en) 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody for the treatment of cancer
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
NO2195023T3 (de) 2007-08-29 2018-08-04
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
AR070821A1 (es) 2008-03-12 2010-05-05 Imclone Llc Anticuerpo anti- tyrp1 (antitiroxina humana)
DK2324060T3 (en) 2008-09-07 2015-10-26 Glyconex Inc ANTI-EXTENDED TYPE I glycosphingolipid ANTIBODY, DERIVATIVES AND USE
JP5925678B2 (ja) 2009-08-18 2016-05-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 増殖性および病原性疾患の治療のための方法および組成物
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
CN102844050B (zh) 2010-02-19 2019-02-05 康奈尔大学 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
KR20220012894A (ko) 2019-05-24 2022-02-04 사노피 전신 경화증의 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088994B1 (de) * 1982-03-15 1991-06-19 Schering Corporation Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) * 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.

Also Published As

Publication number Publication date
JPH03500005A (ja) 1991-01-10
EP0338745B1 (de) 1995-03-01
JPH11225758A (ja) 1999-08-24
JP3105898B2 (ja) 2000-11-06
CA1341411C (en) 2002-12-17
ES2070172T3 (es) 1995-06-01
EP0338745A1 (de) 1989-10-25
GR3015248T3 (en) 1995-06-30
DE68921364T2 (de) 1995-06-29
DE68921364D1 (de) 1995-04-06
AU3536489A (en) 1989-11-03
WO1989009825A1 (en) 1989-10-19
AU627183B2 (en) 1992-08-20

Similar Documents

Publication Publication Date Title
ATE119198T1 (de) Verfahren zur herstellung von proteinen mittels rekombinanter dna.
ATE91716T1 (de) Verfahren zur herstellung vielkettige polypeptide oder proteine.
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DK368588D0 (da) Bindingsmolekyler med en enkelt plypeptidkaede
DE69826465D1 (de) Verfahren zur in vitro evolution von proteinfunktionen
ATE397061T1 (de) Verfahren zur herstellung von proteinen
DK1246917T3 (da) Humane Stra6-polypeptider
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
Remington et al. Biosynthesis of a disulphide-bonded short-chain collagen by calf growth-plate cartilage
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
FI102383B1 (fi) Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
ATE72458T1 (de) Zugeordnete ribosomen und ihre verwendung zur herstellung von proteinen aus zellkulturen.
HUP9801330A2 (hu) Új PKA-kötő fehérjék és alkalmazásuk
ATE162853T1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
EP0688224A4 (de) Ein mutiertes protein und verfahren und materialien zu seiner herstellung und verwendung
DE60040789D1 (de) Verfahren zur aufreinigung heterologer proteine
DE69634297D1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
DE69721629D1 (de) An Nukleinsäure gebundenes Polypeptid, Verfahren zur Herstellung eines an Nukleinsäure gebundenen Polypeptides und Immunoassay, in dem dieses Polypeptid Verwendung findet
DK1249491T3 (da) Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder